Erasca’s ERAS-801 gains FDA orphan drug designation for glioblastoma
Erasca has obtained orphan drug designation (ODD) from the US FDA for ERAS-801 to treat malignant glioma, including glioblastoma
Erasca has obtained orphan drug designation (ODD) from the US FDA for ERAS-801 to treat malignant glioma, including glioblastoma
What's Your Reaction?
